apo-galantamine mr galantamine (as hydrobromide) 8 mg modified release capsules blister pack
arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ethylcellulose; gelatin; magnesium stearate - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
galantamine sr ch galantamine (as hydrobromide) 8mg modified release capsules blister pack
southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; ethylcellulose; titanium dioxide; hypromellose; gelatin; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
galantamine sr scp galantamine (as hydrobromide) 8mg modified release capsules blister pack
southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; ethylcellulose; titanium dioxide; hypromellose; gelatin; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
gamine xr galantamine (as hydrobromide) 8mg modified release capsules blister pack
arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; magnesium stearate; microcrystalline cellulose; ethylcellulose; titanium dioxide - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
galantamine sz galantamine (as hydrobromide) 8mg modified release capsules blister pack
southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; gelatin; ethylcellulose; microcrystalline cellulose; titanium dioxide; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
galantamine hydrobromide capsule, extended release
aphena pharma solutions - tennessee, llc - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 16 mg - galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine hydrobromide extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.
apo-galantamine mr galantamine (as hydrobromide) 16 mg modified release capsules blister pack
arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: iron oxide red; hypromellose; titanium dioxide; magnesium stearate; microcrystalline cellulose; ethylcellulose; gelatin - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
apo-galantamine mr galantamine (as hydrobromide) 24 mg modified release capsules blister pack
arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: erythrosine; ethylcellulose; titanium dioxide; iron oxide yellow; hypromellose; magnesium stearate; iron oxide red; gelatin; microcrystalline cellulose; indigo carmine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type
galantamine- galantamine tablet, film coated
mylan pharmaceuticals inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg - galantamine tablets are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. there are no adequate and well-controlled studies in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically. galantamine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in rats, administration of galantamine (oral doses of 2 mg/kg/day, 8 mg/kg/day, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal skeletal variations at the two highest doses. th
galantamine- galantamine tablet, film coated
mylan institutional inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg - galantamine tablets are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. there are no adequate and well-controlled studies in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically. galantamine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in rats, administration of galantamine (oral doses of 2 mg/kg/day, 8 mg/kg/day, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal skeletal variations at the two highest doses. th